AYOXXA develops multiplex assay for stratification of sepsis patients using soluble biomarkers
Cologne, Germany, September 25, 2017 - AYOXXA Biosystems GmbH, an international biotechnology company, will develop a multiplex assay to support the treatment of sepsis patients as part of the project "SepsisData.Net.NRW - Digitized Pattern Recognition for Personalized Treatment of Sepsis Patients". The development will be based on the Company’s innovative bead-based protein analysis platform LUNARIS™.
AYOXXA launches LUNARIS Mouse 12-Plex Th17 Kit to elucidate Th17 cell biology
Cologne, Germany, September 18, 2017 - AYOXXA Biosystems GmbH, an international biotechnology company, focused on the development of innovative multiplex protein analysis technologies enabling translational research in basic and clinical research, today announced the expansion of its catalogue of immunoassays for multiplex protein analysis with the introduction of LUNARIS™ Mouse 12-Plex Th17 Kit for the quantitative analysis of soluble mouse T helper 17 (Th17) cell-related markers. The assay is optimized for usage on LUNARIS™, AYOXXA’s innovative multiplex protein analysis system.
AYOXXA introduces LUNARIS™, its advanced fully integrated low-volume beads-on-a-chip multiplex protein analysis system
Cologne, Germany, September 11, 2017 - AYOXXA Biosystems GmbH, an international biotechnology company, today announces the introduction of its advanced low-volume beads-on-a-chip multiplex protein analysis system. The LUNARIS™ system can be readily integrated into any laboratory routine and is optimized to provide easy-to-use, standardized workflow from sample to result.
AYOXXA at Sachs 17th Annual Biotech in Europe Forum
Rodney Turner, CEO of AYOXXA is scheduled to talk about recent and further developments of the Company and will participate in the panel discussion on Diagnostics & Imaging.
This year, Sachs Forum for Global Partnering & Investment will take place in
Basel, Congress Center, Switzerland.